
Commentary|Videos|January 13, 2023
Adverse Events Seen With Combination Lenvatinib and Pembrolizumab for Recurrent Endometrial Cancer
Kimberly A. Spickes, CNP, details the adverse events she sees with combination lenvatinib and pembrolizumab treatment for recurrent endometrial cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Oncology Nursing News
1
NCCN Survey: US Cancer Centers Face Generic Oncology Drug Shortages
2
FDA Grants Final Approval to Cabozantinib Capsules Across Multiple Solid Tumor Indications
3
Updated ASTRO Pancreatic Guidelines: Key Takeaways for Oncology Nurses
4
KEYNOTE-564 5-Year Data: Adjuvant Pembrolizumab Benefits ccRCC
5







































































